O. Katopodis

Sixty-day all-cause mortality rates in patients treated for gastrointestinal cancers, in randomised trials, at the Royal Marsden Hospital.

A. Norman, D. Cunningham, P. Ross, 2004, European journal of cancer.

Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG)

V. Georgoulias, E. Stathopoulos, J. Souglakos, 2014, Cancer Chemotherapy and Pharmacology.

Second-line chemotherapy with Capecitabine (Xeloda) and Docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial

D. Mavroudis, V. Georgoulias, A. Polyzos, 2011, Cancer Chemotherapy and Pharmacology.

Expansion of CD8+ T cells that express low levels of the B cell‐specific molecule CD20 in patients with multiple myeloma

M. Dimopoulos, P. Sfikakis, S. Liossis, 2003, British journal of haematology.

Elderly patients with fluoropyrimidine-resistant advanced colorectal cancer (CRC) derive similar benefit without excessive toxicity when treated with irinotecan monotherapy

A. Norman, D. Cunningham, P. Ross, 2004 .